Cargando…
Kinetics of antibody responses dictate COVID-19 outcome
Recent studies have provided insights into innate and adaptive immune dynamics in coronavirus disease 2019 (COVID-19). Yet, the exact feature of antibody responses that governs COVID-19 disease outcomes remain unclear. Here, we analysed humoral immune responses in 209 asymptomatic, mild, moderate an...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781347/ https://www.ncbi.nlm.nih.gov/pubmed/33398304 http://dx.doi.org/10.1101/2020.12.18.20248331 |
_version_ | 1783631659193597952 |
---|---|
author | Lucas, Carolina Klein, Jon Sundaram, Maria Liu, Feimei Wong, Patrick Silva, Julio Mao, Tianyang Oh, Ji Eun Tokuyama, Maria Lu, Peiwen Venkataraman, Arvind Park, Annsea Israelow, Benjamin Wyllie, Anne L. Vogels, Chantal B. F. Muenker, M. Catherine Casanovas-Massana, Arnau Schulz, Wade L. Zell, Joseph Campbell, Melissa Fournier, John B. Grubaugh, Nathan D. Farhadian, Shelli Wisnewski, Adam V. Cruz, Charles Dela Omer, Saad Ko, Albert I. Ring, Aaron Iwasaki, Akiko |
author_facet | Lucas, Carolina Klein, Jon Sundaram, Maria Liu, Feimei Wong, Patrick Silva, Julio Mao, Tianyang Oh, Ji Eun Tokuyama, Maria Lu, Peiwen Venkataraman, Arvind Park, Annsea Israelow, Benjamin Wyllie, Anne L. Vogels, Chantal B. F. Muenker, M. Catherine Casanovas-Massana, Arnau Schulz, Wade L. Zell, Joseph Campbell, Melissa Fournier, John B. Grubaugh, Nathan D. Farhadian, Shelli Wisnewski, Adam V. Cruz, Charles Dela Omer, Saad Ko, Albert I. Ring, Aaron Iwasaki, Akiko |
author_sort | Lucas, Carolina |
collection | PubMed |
description | Recent studies have provided insights into innate and adaptive immune dynamics in coronavirus disease 2019 (COVID-19). Yet, the exact feature of antibody responses that governs COVID-19 disease outcomes remain unclear. Here, we analysed humoral immune responses in 209 asymptomatic, mild, moderate and severe COVID-19 patients over time to probe the nature of antibody responses in disease severity and mortality. We observed a correlation between anti-Spike (S) IgG levels, length of hospitalization and clinical parameters associated with worse clinical progression. While high anti-S IgG levels correlated with worse disease severity, such correlation was time-dependent. Deceased patients did not have higher overall humoral response than live discharged patients. However, they mounted a robust, yet delayed response, measured by anti-S, anti-RBD IgG, and neutralizing antibody (NAb) levels, compared to survivors. Delayed seroconversion kinetics correlated with impaired viral control in deceased patients. Finally, while sera from 89% of patients displayed some neutralization capacity during their disease course, NAb generation prior to 14 days of disease onset emerged as a key factor for recovery. These data indicate that COVID-19 mortality does not correlate with the cross-sectional antiviral antibody levels per se, but rather with the delayed kinetics of NAb production. |
format | Online Article Text |
id | pubmed-7781347 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-77813472021-01-05 Kinetics of antibody responses dictate COVID-19 outcome Lucas, Carolina Klein, Jon Sundaram, Maria Liu, Feimei Wong, Patrick Silva, Julio Mao, Tianyang Oh, Ji Eun Tokuyama, Maria Lu, Peiwen Venkataraman, Arvind Park, Annsea Israelow, Benjamin Wyllie, Anne L. Vogels, Chantal B. F. Muenker, M. Catherine Casanovas-Massana, Arnau Schulz, Wade L. Zell, Joseph Campbell, Melissa Fournier, John B. Grubaugh, Nathan D. Farhadian, Shelli Wisnewski, Adam V. Cruz, Charles Dela Omer, Saad Ko, Albert I. Ring, Aaron Iwasaki, Akiko medRxiv Article Recent studies have provided insights into innate and adaptive immune dynamics in coronavirus disease 2019 (COVID-19). Yet, the exact feature of antibody responses that governs COVID-19 disease outcomes remain unclear. Here, we analysed humoral immune responses in 209 asymptomatic, mild, moderate and severe COVID-19 patients over time to probe the nature of antibody responses in disease severity and mortality. We observed a correlation between anti-Spike (S) IgG levels, length of hospitalization and clinical parameters associated with worse clinical progression. While high anti-S IgG levels correlated with worse disease severity, such correlation was time-dependent. Deceased patients did not have higher overall humoral response than live discharged patients. However, they mounted a robust, yet delayed response, measured by anti-S, anti-RBD IgG, and neutralizing antibody (NAb) levels, compared to survivors. Delayed seroconversion kinetics correlated with impaired viral control in deceased patients. Finally, while sera from 89% of patients displayed some neutralization capacity during their disease course, NAb generation prior to 14 days of disease onset emerged as a key factor for recovery. These data indicate that COVID-19 mortality does not correlate with the cross-sectional antiviral antibody levels per se, but rather with the delayed kinetics of NAb production. Cold Spring Harbor Laboratory 2020-12-22 /pmc/articles/PMC7781347/ /pubmed/33398304 http://dx.doi.org/10.1101/2020.12.18.20248331 Text en https://creativecommons.org/licenses/by-nd/4.0/This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, and only so long as attribution is given to the creator. The license allows for commercial use. |
spellingShingle | Article Lucas, Carolina Klein, Jon Sundaram, Maria Liu, Feimei Wong, Patrick Silva, Julio Mao, Tianyang Oh, Ji Eun Tokuyama, Maria Lu, Peiwen Venkataraman, Arvind Park, Annsea Israelow, Benjamin Wyllie, Anne L. Vogels, Chantal B. F. Muenker, M. Catherine Casanovas-Massana, Arnau Schulz, Wade L. Zell, Joseph Campbell, Melissa Fournier, John B. Grubaugh, Nathan D. Farhadian, Shelli Wisnewski, Adam V. Cruz, Charles Dela Omer, Saad Ko, Albert I. Ring, Aaron Iwasaki, Akiko Kinetics of antibody responses dictate COVID-19 outcome |
title | Kinetics of antibody responses dictate COVID-19 outcome |
title_full | Kinetics of antibody responses dictate COVID-19 outcome |
title_fullStr | Kinetics of antibody responses dictate COVID-19 outcome |
title_full_unstemmed | Kinetics of antibody responses dictate COVID-19 outcome |
title_short | Kinetics of antibody responses dictate COVID-19 outcome |
title_sort | kinetics of antibody responses dictate covid-19 outcome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781347/ https://www.ncbi.nlm.nih.gov/pubmed/33398304 http://dx.doi.org/10.1101/2020.12.18.20248331 |
work_keys_str_mv | AT lucascarolina kineticsofantibodyresponsesdictatecovid19outcome AT kleinjon kineticsofantibodyresponsesdictatecovid19outcome AT sundarammaria kineticsofantibodyresponsesdictatecovid19outcome AT liufeimei kineticsofantibodyresponsesdictatecovid19outcome AT wongpatrick kineticsofantibodyresponsesdictatecovid19outcome AT silvajulio kineticsofantibodyresponsesdictatecovid19outcome AT maotianyang kineticsofantibodyresponsesdictatecovid19outcome AT ohjieun kineticsofantibodyresponsesdictatecovid19outcome AT tokuyamamaria kineticsofantibodyresponsesdictatecovid19outcome AT lupeiwen kineticsofantibodyresponsesdictatecovid19outcome AT venkataramanarvind kineticsofantibodyresponsesdictatecovid19outcome AT parkannsea kineticsofantibodyresponsesdictatecovid19outcome AT israelowbenjamin kineticsofantibodyresponsesdictatecovid19outcome AT wyllieannel kineticsofantibodyresponsesdictatecovid19outcome AT vogelschantalbf kineticsofantibodyresponsesdictatecovid19outcome AT muenkermcatherine kineticsofantibodyresponsesdictatecovid19outcome AT casanovasmassanaarnau kineticsofantibodyresponsesdictatecovid19outcome AT schulzwadel kineticsofantibodyresponsesdictatecovid19outcome AT zelljoseph kineticsofantibodyresponsesdictatecovid19outcome AT campbellmelissa kineticsofantibodyresponsesdictatecovid19outcome AT fournierjohnb kineticsofantibodyresponsesdictatecovid19outcome AT kineticsofantibodyresponsesdictatecovid19outcome AT grubaughnathand kineticsofantibodyresponsesdictatecovid19outcome AT farhadianshelli kineticsofantibodyresponsesdictatecovid19outcome AT wisnewskiadamv kineticsofantibodyresponsesdictatecovid19outcome AT cruzcharlesdela kineticsofantibodyresponsesdictatecovid19outcome AT omersaad kineticsofantibodyresponsesdictatecovid19outcome AT koalberti kineticsofantibodyresponsesdictatecovid19outcome AT ringaaron kineticsofantibodyresponsesdictatecovid19outcome AT iwasakiakiko kineticsofantibodyresponsesdictatecovid19outcome |